Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy

Trial Profile

Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy

Suspended
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Talacotuzumab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms SAMBA-trial
  • Most Recent Events

    • 04 Sep 2017 Status changed from recruiting to suspended.
    • 16 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top